Hostname: page-component-586b7cd67f-t8hqh Total loading time: 0 Render date: 2024-12-01T03:44:06.436Z Has data issue: false hasContentIssue false

Does Second Place Count? Lessons from a Major Discrepancy Between Carbapenem-Resistant Klebsiella pneumoniae and Carbapenem-Resistant Enterobacter cloacae in a One-Year Follow-Up Study

Published online by Cambridge University Press:  06 March 2017

Leandro Reus Rodrigues Perez*
Affiliation:
Hospital Mãe de Deus, Porto Alegre, Brazil Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
*
Address correspondence to Leandro Reus Rodrigues Perez, PhD, Microbiology Unit - Hospital Mãe de Deus, 286, José de Alencar Street, 90610-000, Porto Alegre – RS, Brazil ([email protected]).
Rights & Permissions [Opens in a new window]

Abstract

Type
Letters to the Editor
Copyright
© 2017 by The Society for Healthcare Epidemiology of America. All rights reserved 

To the Editor—Carbapenem-resistant Enterobacteriaceae (CREs) have become one of the most prevalent agents in nosocomial infections, and they are associated with poor outcomes.Reference Tamma, Goodman, Harris, Tekle, Roberts, Taiwo and Simner 1 In many Brazilian hospitals, Klebsiella pneumoniae carbapenemase (KPC)–producing K. pneumoniae (Kp), a main representative of the CRE group, has reached endemic levels and has been responsible for high morbidity and mortality rates.Reference Perez 2 , Reference Rodrigues 3

Since the emergence of KPC Kp, practically no other microorganism has managed to achieve prevalence levels as severe as those achieved by KPC Kp.Reference Perez 2 , Reference Perez 4 , Reference Perez 5 Some studies have shown the emergence of Enterobacter spp, especially Enterobacter cloacae and Enterobacter aerogenes, as a reflection of an increased prevalence rate, and they implicate CREs as one of the main bacteria with the ability to acquire and develop antimicrobial resistance, including carbapenem agents.Reference Ronveaux, Gheldre, Glupczynski, Struelens and Mol 6 , Reference Gales, Jones and Sader 7

In the past few years, the emergence of Enterobacter spp has been considered a second epidemic subsequent to the epidemic wave of KPC-producing microorganisms. However, in Brazil, few data are available to reveal how this microorganism has evolved over time, despite its recognized clinical and epidemiological status.

To verify the crude prevalence rate of CREs and to recognize a possible second potential CRE agent and assess its differences in relation to the most prevalent CRE, a retrospective survey from January 1 to December 26, 2016, was conducted at a tertiary hospital in Porto Alegre, Southern Brazil.

Identification of bacterial species as well as an antimicrobial susceptibility profile were initially performed using an automated broth microdilution system (MicroScan, Beckman Coulter, Brea, CA); the results were confirmed using the disk diffusion method. Determination of the resistance mechanism attributable to carbapenem agents was performed by applying a synergistic test with phenyl-boronic acid and ethylenediamine tetra-acetic acid for detecting KPC and metallo-betalactamase enzymes, respectively, and by enzymatic inhibition using clavulanic acid and cloxacillin for detecting extended-spectrum β-lactamases (ESBLs) and AmpC enzymes, in that order, as previously described.Reference Perez 2

During the study period, 472 CRE isolates were recovered from clinical sites. Among them, 445 (94.3%) were KPC producers and the remaining 27 isolates (5.7%) were noncarbapenemase producers (nCPs).

Among the KPC-producing isolates, K. pneumoniae (98.9%; 440 of 445) was by far the most prevalent microorganism, followed by Escherichia coli (0.7%; 3 of 445) and Citrobacter freundii (0.4%; 2 of 445). Among the nCP isolates, Enterobacter cloacae (63%; 17 of 27) was the most common agent, and the remaining isolates were E. aerogenes and Serratia marcescens (14.8%; 4 isolates each), and K. pneumoniae and Escherichia coli (3.7%; 1 isolate each).

The crude prevalence rates for all CRE isolates found in this study, not including the carbapenem-resistance mechanism involved (as described above), are illustrated in Figure 1(A). Although the nCP E. cloacae was the second most prevalent CRE, its recovery rate was extremely low compared to KPC Kp (3.6% vs 93.3%, respectively). In addition, the prevalence of nCP E. cloacae decreased over the study period, contrary to the trend observed in other countries.Reference Ronveaux, Gheldre, Glupczynski, Struelens and Mol 6 , Reference Kanamori, Parobek and Juliano 8

FIGURE 1 (A) Crude prevalence of all CRE isolates found in this study and (B) cumulative prevalence of KPC-Kp and nCP-E. cloacae (the 2 most prevalent agents) recovered from some clinical specimens during the study period.

In past few years, K. pneumoniae and E. cloacae have proven to be challenging microorganisms regarding their pathogenesis, transmission, and ability to acquire antimicrobial resistance. Therefore, these organisms are highlighted in a faction of agents termed by the Infectious Diseases Society of America as the ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, K. pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp),Reference Rice 9 and their prevalence rates are not constantly monitored. Likewise, it is important that the differences among them be evaluated to produce a better strategy to combat their spread.

This study produced several conclusions: (1) nCP E. cloacae is the second most prevalent CRE in our institution, and it is far less prevalent than KPC Kp. (2) Different gender and/or species may reflect a better ability to become established in a nosocomial environment. Moreover, 440 of 1,099 of all K. pneumoniae isolates (40%) recovered during the study period were KPC producers, whereas only 17 of 144 of all E. cloacae (11.8%) recovered in the same period were carbapenem-resistant isolates. (3) The type of resistance mechanism (ie, those that confer resistance to broad-spectrum activity agents, such as carbapenems) is as important as gender and/or species differences. Furthermore, the KPC resistance mechanism seems to be more dangerous than any other, such as ESBL or AmpC β-lactamases, efflux pumps, outer membrane impermeability or even a sum of them.

Why does a microorganism with relatively minor virulence and resistance remain a second potential CRE agent? Although this question is still under investigation, a reasonable explanation would be the fact that E. cloacae, like K. pneumoniae, has a greater ability to become resistant to polymyxins, which are currently widely used.Reference Ronveaux, Gheldre, Glupczynski, Struelens and Mol 6 , Reference Kanamori, Parobek and Juliano 8

In conclusion, the results of this study confirm KPC Kp as the most prevalent CRE, far more prevalent than an nCP E. cloacae isolate, which was the second most common CRE pathogen identified in this survey. The presence of the bla KPC gene seems to be mandatory for this major difference between species. However, a well-structured and well-coordinated surveillance plan must be implemented together with a strict program of antimicrobial use to prevent the spread of the most prevalent CRE as well as the less prevalent CREs.

ACKNOWLEDGMENTS

Financial support: No financial support was provided relevant to this article.

Potential conflicts of interest: All authors report no conflicts of interest relevant to this article.

References

REFERENCES

1. Tamma, PD, Goodman, KE, Harris, AD, Tekle, T, Roberts, A, Taiwo, A, Simner, PJ. Comparing the outcomes of patients with carbapenemase-producing and non-carbapenemase-producing carbapenem-resistant Enterobacteriaceae bacteremia. Clin Infect Dis 2016;64:257264.Google Scholar
2. Perez, LR. Carbapenem-resistant Enterobacteriaceae: a major prevalence difference due to the high performance of carbapenemase producers when compared to the nonproducers. Infect Control Hosp Epidemiol 2015;36:14801482.Google Scholar
3. Rodrigues, Perez. Emergence of infections due to a polymyxin B-resistant KPC-2-producing Klebsiella pneumoniae in critically ill patients: What is the role of a previous colonization? Infect Control Hosp Epidemiol 2015;37:240241.Google Scholar
4. Perez, LR. Increase in prevalence of KPC-2-producing Klebsiella pneumoniae recovered from respiratory secretions of intensive care patients—getting a free ride on a menacing colistin resistance. Infect Control Hosp Epidemiol 2016;37:15211522.Google Scholar
5. Perez, LR. The impact of carbapenem-resistant Enterobacteriaceae type on clinical outcomes after the recovery of this organism from urine of critically ill patients. Infect Control Hosp Epidemiol 2016;37:12571258.Google Scholar
6. Ronveaux, O, Gheldre, Y, Glupczynski, Y, Struelens, M, Mol, P. Emergence of Enterobacter aerogenes as a major antibiotic-resistant nosocomial pathogen in Belgian hospitals. Clin Microbiol Infect 1999;5:622627.Google Scholar
7. Gales, AC, Jones, RN, Sader, HS. Global assessment of the antimicrobial activity of polymyxin B against 54731 clinical isolates of gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001–2004). Clin Microbiol Infect 2006;12:315321.Google Scholar
8. Kanamori, H, Parobek, CM, Juliano, JJ, et al. A prolonged outbreak of KPC-3-producing Enterobacter cloacae and Klebsiella pneumoniae driven by multiple mechanisms of resistance transmission at a large academic burn center. Antimicrob Agents Chemother 2016. doi: 10.1128/AAC.01516-16.Google Scholar
9. Rice, LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis 2008;197:10791081.Google Scholar
Figure 0

FIGURE 1 (A) Crude prevalence of all CRE isolates found in this study and (B) cumulative prevalence of KPC-Kp and nCP-E. cloacae (the 2 most prevalent agents) recovered from some clinical specimens during the study period.